WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Dr Reddy’s launches Bosutinib tablets in US market

Dr. Reddy’s launches Bosutinib tablets in the US, enhancing its oncology portfolio through collaboration with MSN Laboratories.

Raccontata dathehindubusinessline.commorningstar.comthehindu.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
thehindubusinessline.comStai leggendo3 g fa

Dr Reddy’s launches Bosutinib tablets in US market

Dr. Reddy’s launches Bosutinib tablets in the US, enhancing its oncology portfolio through collaboration with MSN Laboratories.

originale
thehindu.com3 g fa

Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.

Dr. Reddy's launches generic Bosutinib 400mg with 180-day U.S. exclusivity; brand equivalent (Bosulif) had $253.8M annual sales. The first-to-file advantage signals India's complex oncology capability and cost pressure on branded cancer therapies for healthcare portfolios.

Leggi questa versione → originale
morningstar.com3 g fa

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of…

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

Leggi questa versione → originale

Timeline cronologica

  1. sabato 13 giugno 2026·thehindubusinessline.com

    Dr Reddy’s launches Bosutinib tablets in US market

    Dr. Reddy’s launches Bosutinib tablets in the US, enhancing its oncology portfolio through collaboration with MSN Laboratories.

  2. sabato 13 giugno 2026·morningstar.com

    Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

    Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

  3. sabato 13 giugno 2026·thehindu.com

    Dr. Reddy’s launches generic cancer drug Bosutinib in U.S.

    Dr. Reddy’s launches Bosutinib, a generic cancer drug, in the U.S., enhancing access to critical oncology treatments.